Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled trial

American Heart Journal

Volumn 137, Issue 6, 1999, Pages 1062-1069

  Nørgaard, Bjarne Linde ^a   Wachtell, Kristian ^b   Christensen, Per Dahl ^b   Madsen, Bruno ^b   Johansen, Jens Brock ^b   Christiansen, Evald Høj ^b   Graff, Ole ^b   Simonsen, Erik Hertel ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOFETILIDE; MAGNESIUM CHLORIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART ELECTROPHYSIOLOGY; HEART RATE; HEMODYNAMICS; HOLTER MONITORING; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TORSADE DES POINTES;

EID: 0033404112     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70363-7     Document Type: Article

References (24)

1. Pritchett ELC. Management of atrial fibrillation. N Engl J Med 1992; 326:1264-71.
2. Prystowsky EN, Benson DW, Fuster V, et al. Management of patients with atrial fibrillation. Circulation 1996;93:1262-77.
3. Goy J-J, Grbic M, Hurni M, et al. Conversion of supraventricular arrhythmias to sinus rhythm using flecainide. Eur Heart J 1985;6:518-24.
4. Hohnloser SH, Van De Loo A, Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. J Am Coll Cardiol 1995;26:852-8.
5. Rasmussen HS, Allen MJ, Blackburn KJ, et al. Dofetilide, a novel class III antiarrhythmic agent. J Cardiovasc Pharmacol 1992;20(suppl 2):96-105.
6. Suttorp MJ, Polak PE, Van't Hof A, et al. Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter. Am J Cardiol 1992;69:417-9.
7. Falk RH, Pollak A, Singh SN, et al, for the Intravenous Dofetilide Investigators. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation and flutter. J Am Coll Cardiol 1997;29:385-90.
8. Singh SN, Falk R, Friedrich T, et al, and the Dofetilide Study Group. The efficacy and safety of dofetilide in patients with recent onset atrial fibrillation or flutter. Circulation 1993;88(suppl I): I-65.
9. Gosselink ATM, Kooistra M, Kingma JH, et al. Efficacy and safety of intravenous dofetilide in atrial fibrillation or flutter. Circulation 1993;88(suppl I):I-396.
10. Capucci A, Lenzi T, Boriani G, et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol 1992;70:69-72.
11. Fresco C, Proclemer A, Pavan A, et al. Intravenous propafenone in paroxysmal atrial fibrillation: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Clin Cardiol 1996;19:409-12.
12. Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 1996;28:130-6.
13. Stambler BS, Wood MA, Ellenbogen KA, et al, and the Ibutilide Repeat Dose Study Investigators. Efficacy and safety of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996;94:1613-21.
14. Donovan KD, Dobb GJ, Coombs LJ, et al. Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide. Am J Cardiol 1991;67:137-41.
15. Suttorp MJ, Kingma JH, Lie-A-Huen L, et al. Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol 1989;63:693-6.
16. Bianconi L, Boccadamo R, Pappalardo A, et al. Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. Am J Cardiol 1989;64:335-8.
17. Suttorp MJ, Kingma JH, Jessurun ER, et al. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 1990;16:1722-7.
18. Sung RJ, Tan HL, Karagounis L, et al. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Am Heart J 1995;129:739-48.
19. Singh BN. Acute conversion of atrial fibrillation and flutter: direct current cardioversion versus intravenously administered pure class III agents. J Am Coll Cardiol 1997;29:391-3.
20. Demolis JL, Funck-Brentano C, Ropers J, et al. Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans. Circulation 1996;94:1592-9.
21. Wang Z, Pelletier LC, Talajic M, et al. Effects of flecainide and quinidine on human atrial action potentials: role of rate-dependence and comparison with guinea pig, rabbit, and dog tissues. Circulation 1990;82:274-83.
22. Singh BN. When is QT prolongation antiarrhythmic and when is it proarrhythmic? Am J Cardiol 1989;63:867-9.
23. Bianconi L, Dinelli M, Pappalardo A, et al. Comparison of intravenously-administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Circulation 1995;92(suppl I): I-774.
24. Carlsson L, Abrahamsson C, Andersson B, et al. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early after depolarisations. Cardiovasc Res 1993;27:2186-93.